SKYE (Skye Bioscience) Retained Earnings : $-130.95 Mil (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Skye Bioscience Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Skye Bioscience's retained earnings for the quarter that ended in Dec. 2024 was $-130.95 Mil.

Skye Bioscience's quarterly retained earnings declined from Jun. 2024 ($-117.31 Mil) to Sep. 2024 ($-121.20 Mil) and declined from Sep. 2024 ($-121.20 Mil) to Dec. 2024 ($-130.95 Mil).

Skye Bioscience's annual retained earnings declined from Dec. 2022 ($-66.74 Mil) to Dec. 2023 ($-104.38 Mil) and declined from Dec. 2023 ($-104.38 Mil) to Dec. 2024 ($-130.95 Mil).

Skye Bioscience Retained Earnings Historical Data

The historical data trend for Skye Bioscience's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skye Bioscience Retained Earnings Chart

Skye Bioscience Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Retained Earnings

Get a 7-Day Free Trial

-38.73

-47.26

-66.74

-104.38

-130.95

Skye Bioscience Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Retained Earnings	Get a 7-Day Free Trial															-104.38	-109.40	-117.31	-121.20	-130.95

Skye Bioscience Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Skye Bioscience (NAS:SKYE) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Skye Bioscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Skye Bioscience Inc (NAS:SKYE) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

09R:Germany

Address

11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130

Website

https://www.skyebioscience.com

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Executives

Paul A. Grayson	director	10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Kaitlyn Melanie Arsenault	officer: Chief Financial Officer	11250 EL CAMINO REAL, SUITE 100, C/O SKYE BIOSCIENCE, INC., SAN DIEGO CA 92130
Punit Dhillon	director	5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
5am Partners Vii, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Andrew J. Schwab	director, 10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
John D Diekman	10 percent owner	C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Vii, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar	10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Ii, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Co-investors Ii Lp	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Venture Capital Iii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Iii, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Scott M Rocklage	10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Ii Lp	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107